This image is not available for purchase in your country.

Vildagliptin diabetes drug molecule

Vildagliptin diabetes drug molecule

A624/0531

Rights Managed

This image is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

DR TIM EVANS / SCIENCE PHOTO LIBRARY DR TIM EVANS / SCIENCE PHOTO LIBRARY

Caption

Vildagliptin diabetes drug molecule, computer model. Vildagliptin, which is marketed as Galvus by Novartis, belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It works to reduces hyperglycemia (high blood sugar) in type II diabetes, by inhibiting the inactivation of the hormones GLP-1 and GIP. This results in the secretion of insulin (the hormone that regulates blood glucose levels) in the beta cells and the suppression of glucagon release (which leads to raised blood glucose levels) by the alpha cells of the islets of Langerhans in the pancreas. Atoms, represented as tubes, are colour-coded: carbon (yellow), hydrogen (white), nitrogen (green) and oxygen (pink).

Release details

Model release not required. Property release not required.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Add to board
  • Similar {{ mediaType(i) }}